For the year ending 2025-12-31, PASG had $8,730K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -45,522 |
| Depreciation and amortization | 728 |
| Sharebased compensation | 3,001 |
| Amortization of premium and discount on marketable securities, net | 129 |
| Impairment of long-lived assets | 6,145 |
| Other non-cash items | 14 |
| Prepaid expenses and other current assets, and other assets | -228 |
| Prepaid research and development | -391 |
| Non-refundable sublicense and transition services payments received | 4,015 |
| Right of use assets and operating lease liabilities | 464 |
| Accounts payable | 1,880 |
| Accrued expenses and other current liabilities | -2,054 |
| Net cash provided by (used in) operating activities | -31,509 |
| Sales or maturities of marketable securities | 39,046 |
| Sales of property and equipment and other assets | 1,170 |
| Net cash provided by (used in) investing activities | 40,216 |
| Proceeds from the issuance of common stock under employee stock purchase plan | 23 |
| Net cash provided by (used in) financing activities | 23 |
| Net increase (decrease) in cash and cash equivalents | 8,730 |
| Cash and cash equivalents at beginning of year | 37,573 |
| Cash and cash equivalents at end of year | 46,303 |
Passage BIO, Inc. (PASG)
Passage BIO, Inc. (PASG)